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Abstract
Background Although beta blockers (BBs) are estab-
lished therapy in heart failure, some patients whose left
ventricular ejection fraction (LVEF) initially increases on
BB therapy experience a subsequent LVEF decline. This
study aimed to evaluate the proportion of patients with
non-ischemic cardiomyopathy (NICM) whose LVEF
declines while on BB therapy and determine important
predictors of LVEF decline.
Methods A retrospective analysis of 238 patients receiv-
ing a BB (carvedilol, metoprolol succinate, or tartrate), with
an ejection fraction of B40 % and NICM, whose LVEF
initially rose C5 % after 1 year of BB therapy, was con-
ducted. Post-response LVEF decline C5 % to a final LVEF
of B35 % was evaluated within 4 years of BB initiation.
Results In our study, we had 52 Caucasians (22 %), 78
Hispanics (33 %), and 108 African Americans (45 %).
Overall, 32 patients (13.44 %) had post-response LVEF
decline. The nadir LVEF of patients with post-response
LVEF decline was 25 % (interquartile range 20–27).
Compared with others, Hispanics had lower nadir LVEF
(22 %, p \ 0.001). Important predictors of LVEF decline
were Hispanic race (odds ratio (OR) 6.094, p \ 0.001),
New York Heart Association (NYHA) class (OR 2.287,
p \ 0.05), baseline LVEF (OR 1.075, p \ 0.05), and age
(OR 0.933, p \ 0.001).
Conclusion A significant proportion (13.44 %) of NICM
patients with LVEF increase over 1 year of BB therapy
experienced subsequent LVEF decline. Race, NYHA class,
baseline LVEF, and age are important predictors of this
decline.
1 Introduction
Heart failure (HF) is a major public health problem [1–3]
with poor outcomes especially in African Americans (AA)
and Hispanics [1, 4]. The higher mortality in these groups
has been attributed to differences in the severity and causes
of HF, the prevalence of coexisting conditions and risk
factors [2], socioeconomic and cultural factors, and access
to high-quality medical care [5].
Beta blockers (BBs) are beneficial in patients with symp-
tomatic HF or left ventricular (LV) systolic dysfunction [6–
8]. The increase in left ventricular ejection fraction (LVEF) is
greater in patients with lower baseline LVEF after treatment
with BB therapy [9, 10]. It has been suggested that after
response to BB therapy, the BB should not be withdrawn,
because of an increased risk of clinical deterioration or death
from progressive congestive heart failure (CHF) [11].
However, response to BBs may vary among different
ethnic groups [12–14]. There may be race-related genetic
differences in the beta-adrenergic pathway explaining
that difference. Differences such as the frequency of the
G-protein-coupled receptor kinase (GRK)-Leu41 poly-
morphism, which desensitizes beta-adrenergic receptors,
have been found between AA and Caucasian patients [15].
Overall, BBs have been shown to have similar benefits in
both AA and Caucasians [16–20]. Previous HF studies
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have generally been limited to comparisons between AA
and Caucasian populations [2, 12], but there are few
comparative statistics concerning HF in Hispanics, one of
the fastest-growing segments of the US population [21].
For patients who experience an improvement in ven-
tricular performance on BB therapy, there is little data
regarding whether this improved performance is main-
tained on continued BB therapy. Although several studies
have shown improvements in mortality and hospitaliza-
tions for CHF over more than 2 years, there is little data
following LVEF on BB therapy past 1 year [7, 8, 17, 19,
22, 23]. Of special interest is the effect of BBs on non-
ischemic cardiomyopathy (NICM) since the effect of BBs
on LVEF is often unpredictable in this group [7, 24].
Therefore, it is unknown with what frequency LVEF
increase on BB therapy is maintained past 1 year in
patients with HF. Moreover, while substantial information
is available on racial differences in mortality and risk
factors, much less is known about racial differences in
LVEF response to BBs in patients with NICM.
This study aimed to examine the frequency of decline in
LVEF after initial response to BB therapy in patients with
NICM and to compare this frequency between AA, His-
panic, and Caucasian patients.
2 Methods
2.1 Study Population
A total of 238 patients with baseline a left ventricular ejec-
tion fraction (LVEF) of B40 % utilizing BBs (carvedilol,
metoprolol succinate, or tartrate) with NICM who were
followed at the HF clinic of Weiler Hospital of the Albert
Einstein College of Medicine were analyzed retrospectively.
Patients with ischemic and hypertrophic cardiomyopathy,
hemodynamically significant valvular lesions, severe bron-
chospastic lung disease, baseline heart rate (HR)\60/min or
systolic blood pressure (BP) \90 mmHg were excluded.
Patients whose LVEF failed to rise by C5 % after 1 year of
BB therapy were also excluded.
2.2 Study Design
The clinical design was a retrospective study aimed at ana-
lyzing the effects of BBs on LVEF response among a multi-
ethnic population. Approval was granted from the Albert
Einstein College of Medicine Institutional Review Board.
BBs were titrated up to the maximum tolerable dose without
a predefined time schedule. The maximum tolerable dose
was the daily dose over which there was either (1) aggra-
vation of dyspnea or edema, (2) systolic BP\90 mmHg or
HR\60/min at rest, or (3) a need to increase the concomitant
medication for HF. The assignment of race was by self-
report. LVEF was measured using 2-dimensional echocar-
diography and the modified Simpson’s rule. The following
measurements were taken: LVEF before BB therapy, LVEF
after 1 year of BB therapy, and subsequent LVEF mea-
surements while still on BB therapy after 1 year. As in
previous studies [8, 25], LVEF responders to beta blockade
were defined as patients with an absolute increase in LVEF
C5 % after maximal doses of BB. The lowest LVEF at any
time subsequent to the LVEF measurement at 1 year was
noted. If the lowest subsequent LVEF was B35 % and was at
least 5 % lower than LVEF at the end of the first year of BB
therapy, the term ‘post-response LVEF decline’ was
assigned. A high dose of BB was defined similarly to prior
studies [6–8]. For example, a high dose of metoprolol was
defined as C150 mg oral (PO) daily, whereas a high dose of
carvedilol was defined as C50 mg PO daily.
2.3 Statistical Analyses
Statistical analyses were performed using STATA version
12.0 statistical software. A p value of B0.05 was consid-
ered statistically significant. Continuous data are presented
as median and interquartile range in variables that were not
normally distributed, while categorical data are presented
as number (percentage of patients). Comparisons between
groups were made using two-sample t test, one-way
ANOVA or the non-parametric equivalent for continuous
variables and Chi-square test or Fisher’s exact test for
categorical data. Pearson and Spearman correlation coef-
ficients (r) were used to quantify associations between
variables. The effects of beta blockade on LVEF change
after 1 year were compared using paired t test or the non-
parametric equivalent. To determine important predictors
of post-response LVEF decline, we also performed multi-
variable logistic regression analysis.
3 Results
3.1 Clinical Characteristics
This study included 238 patients: 78 Hispanics, 108 AA, and
52 Caucasians. The clinical characteristics of the study
cohort stratified by LVEF response are displayed in Table 1.
Overall, the median age was 62 years. As shown, patients
with post-response LVEF decline were predominantly His-
panics (44 vs. 29 %, p \ 0.01), and more often had intra-
cardiac defibrillator (ICD) (56 vs. 27 %, p \ 0.001)
compared with patients with sustained LVEF response.
Regarding medication use (Table 2), 142 patients (60 %)
received carvedilol, whereas 96 patients (40 %) received
metoprolol. The median dose of carvedilol was 25 mg daily,
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whereas the median dose of metoprolol was 88 mg daily. As
shown, compared with patients with sustained LVEF
response, patients with post-response LVEF decline were on
lower doses of carvedilol (25 vs. 37.5 %, p \ 0.01) but not
metoprolol. Regarding overall dose of BB (combined), there
was no difference between the different LVEF response
groups (higher vs. lower dose). Most of the patients (95 %)
were on an angiotensin-converting enzyme inhibitors
(ACEI) or angiotensin II receptor blockers (ARB).
3.2 Left Ventricular Ejection Fraction (LVEF)
Improvement After Beta Blockade
Among 238 patients with NICM, 32 (13 %) had post-
response LVEF decline and 206 (87 %) had sustained LVEF
response. Overall, there was a significant improvement of
LVEF from baseline after 1 year of BB (30–44 %,
p \ 0.001). Figure 1 shows change in LVEF after BB in
patients with NICM within 4 years after the initial LVEF.
There was no difference in the LVEF before initiation of BB
in the two LVEF response groups (30 vs. 29 %, p = 0.098).
Compared with patients with post-response LVEF decline,
patients with sustained LVEF response had a higher LVEF
at 1 year (47 vs. 41 %, p \ 0.01) and a higher nadir of
LVEF (40 vs. 25 %, p \ 0.001).
Table 3 shows differences in change in LVEF between
different races. Compared with other races, Hispanics had
lower LVEF increase after 1 year of BB (40 %, p \ 0.01)
and lower nadir LVEF in both the post-response LVEF
decline group (22 %, p \ 0.001) and sustained LVEF
response group (32 %, p \ 0.01) (Fig. 2). There was no
difference in the percentage of sustained and post-response
LVEF decline between races.
3.3 Predictors of Post-Response LVEF Decline
Table 4 shows results of the multivariable logistic analysis
using post-response LVEF decline as the outcome of
interest. Hispanic race was a significant predictor of LVEF
decline in both unadjusted (odds ratio (OR) = 3.128,
p \ 0.01) and adjusted analyses (OR 6.094, p \ 0.001).
Age (OR 0.933, p \ 0.001) and baseline LVEF (OR 1.075,
p \ 0.05) also remained significant predictors of post-
response LVEF decline. Gender, New York Heart Asso-
ciation (NYHA) class, use of an ACEI/ARB, and dose of
BB were not significant predictors of LVEF decline. Sim-
ilar results were noted when we examined the post-
response LVEF decline at 1 year (data not shown).
4 Discussion
This study aimed to examine the frequency of decline in
LVEF after initial response to BB therapy and to compare
this frequency between AA, Hispanic, and Caucasian
patients. The primary finding of this study was that there
might be a significant proportion of HF patients whose
LVEF declines after initially responding to BB therapy.
This conclusion is drawn from the observed occurrence of
LVEF decline after initial response to BB therapy at a rate
of 13.44 % over 4 years after the initiation of therapy.
Compared with other races, Hispanics had lower nadir
LVEF (22 %, p \ 0.001). Important predictors of LVEF
decline were Hispanic race, NYHA class, baseline LVEF,
and age, but not gender.
In our study, we found that there seems to exist an
occurrence of LVEF decline after initial response to BB
therapy at a rate of 13.44 % over 4 years after the initiation
of therapy in patients with NICM. Prior studies have shown
Table 1 Clinical characteristics between patients with post-response













Males 126 (53 %) 14 (44 %) 112 (54 %) 0.263
Race 0.247
Caucasians 52 (22 %) 6 (19 %) 46 (22 %) 0.001
Hispanics 78 (33 %) 14 (44 %) 64 (31 %) 0.002
AA 108 (45 %) 12 (38 %) 96 (47 %) 0.842




Diabetes 106 (45 %) 12 (38 %) 94 (46 %) 0.389
HTN 166 (70 %) 24 (75 %) 142 (69 %) 0.487
NYHA class 0.14
I 32 (13 %) 2 (6 %) 30 (15 %)
I–II 22 (9 %) 6 (19 %) 16 (8 %)
II 90 (38 %) 10 (31 %) 80 (39 %)
II–III 44 (18 %) 2 (6 %) 42 (20 %)
[III 50 (21 %) 12 (38 %) 38 (18 %)
ICD 74 (31 %) 18 (56 %) 56 (27 %) 0.001
Valvular
disease
54 (23 %) 4 (13 %) 50 (24 %) 0.176
Dyslipidemia 156 (66 %) 20 (63 %) 136 (66 %) 0.697
CKD 48 (20 %) 4 (13 %) 44 (21 %) 0.245
Smoking 110 (46 %) 10 (31 %) 100 (49 %) 0.09
Alcohol 74 (31 %) 10 (31 %) 64 (31 %) 0.983
p value (Chi-square for categorical variables and Mann–Whitney test
for continuous variables) for comparison between groups (post-
response LVEF decline vs. sustained LVEF response)
AA African Americans, CKD chronic kidney disease, HTN hyper-
tension, ICD intracardiac defibrillator, IQR interquartile range, LVEF
left ventricular ejection fraction, NICM non-ischemic cardiomyopa-
thy, NYHA New York Heart Association
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that patients with NICM may respond better to BBs than
patients with ischemic cardiomyopathy [26–28]. Patients
with NICM have initially increased wall tension due to
dilated LV that causes increased myocardial oxygen
demands. The global subendocardial ischemia might form
a homogeneous substrate for BB action. Therefore BBs
may find a more homogeneous substrate in the first months
after initiation of therapy. During therapy and maybe over
time because of changes in wall stress, this substrate may
change and the effect of BBs in LVEF declines. Another
factor that may explain the percentage of post-response
LVEF decline in patients with NICM may be genetic
variability. Prior studies have shown that patients with
certain beta receptor genotypes were associated with better
clinical response to BBs compared with others [15, 29–32].
Perhaps the patients with post-response LVEF decline have
different polymorphisms than the patients with sustained
LVEF response. Future research aimed at analyzing poly-
morphisms among patients with NICM who do not seem to
have a sustained response to BBs may yield interesting
results.
Interestingly, we found that Hispanics with chronic HF
had worse LVEF response and post-response LVEF decline
after use of a BB compared with other races. To our
knowledge this is one of the first studies to examine dif-
ferences in LVEF response between AA and Hispanics
with NICM. Although the Hispanic population has been
shown to comprise a high-risk cardiovascular group [33–
Table 2 Differences in medications between patients with post-response LVEF decline and patients with sustained LVEF response
Medications All NICM responders after
1 year of BB (N = 238)
Post-response LVEF
decline (n = 32)
Sustained LVEF
response (n = 206)
p value
Carvedilol 142 (60 %) 24 (75 %) 118 (57 %) 0.06
Median-dose carvedilol (mg) (range of dose) 25 (18.75–50) 25 (12.5–25) 37.5 (25–50) 0.020
Low-dose carvedilol (6.25 mg PO bid) (n, %) 35 (15 %) 9 (28 %) 26 (13 %) 0.021
Medium-dose carvedilol (12.5 mg PO bid) 49 (21 %) 11 (34 %) 38 (18 %) 0.038
High-dose carvedilol (25 mg PO bid) 58 (24 %) 4 (13 %) 54 (26 %) 0.093
Metoprolol 96 (40 %) 8 (25 %) 88 (43 %) 0.06
Median-dose metoprolol (mg) 87.5 (50–100) 75 (37.5–150) 87.5 (50–100) 0.811
Low-dose metoprolol (25 mg PO bid) 48 (20 %) 4 (13 %) 44 (21 %) 0.245
Medium-dose metoprolol (50 mg PO bid) 27 (11 %) 2 (6 %) 25 (12 %) 0.329
High-dose metoprolol ([75 mg PO bid) 21 (9 %) 2 (6 %) 19 (9 %) 0.581
Overall dose of BB (combined)
Low 83 (35 %) 13 (41 %) 70 (34 %) 0.463
Medium 76 (32 %) 13 (41 %) 63 (31 %) 0.257
High 79 (33 %) 6 (19 %) 73 (35 %) 0.062
ACEI or ARB 226 (95 %) 30 (94 %) 196 (95 %) 0.737
Hydralazine 40 (17 %) 2 (6 %) 38 (18 %) 0.086
Nitrates 32 (13 %) 0 (0 %) 32 (16 %) 0.017
Spironolactone 134 (56 %) 22 (69 %) 112 (54 %) 0.127
Digoxin 120 (50 %) 14 (44 %) 106 (51 %) 0.417
Calcium channel blocker 42 (18 %) 4 (13 %) 38 (18 %) 0.412
p value (Chi-square for categorical variables and Mann–Whitney test for continuous variables) for comparison between groups (post-response
LVEF decline vs. sustained LVEF response)
ACEI Angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, BB beta blocker, bid twice daily, LVEF left ventricular
ejection fraction, NICM non-ischemic cardiomyopathy, PO oral
Fig. 1 Change in LVEF after BB in patients with NICM. Compared
with patients with post-response LVEF decline, patients with
sustained LVEF response had higher LVEF at 1 year (47 vs. 41 %,
p \ 0.01) and higher nadir of LVEF (40 vs. 25 %, p \ 0.001). BB
beta blocker, LVEF left ventricular ejection fraction, NICM non-
ischemic cardiomyopathy
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35], there are very limited data on Hispanic patients with
chronic systolic HF. AA have been underrepresented in
major HF trials, whereas Hispanic patients have been
nearly absent in most clinical trials, and thus there are very
limited data regarding the effect of medications such as
BBs in this ethnic group. Although LVEF patterns in
Hispanic subgroups compared with non-Hispanic whites
have been examined in the MESA (Multi-Ethnic Study of
Atherosclerosis) [34, 35], these patterns have not been
associated with use of BBs. In our study, we confirm prior
findings that Hispanics have differences in clinical
response of HF parameters compared with other races [36].
Finally, we extended this finding by showing that His-
panics have worse LVEF response and post-response
LVEF decline compared with other races after use of BBs.
The different LVEF response to BBs among races can be
explained by a few factors [12–14]. A difference in LVEF
response and LVEF decline can be explained by differences
among ethnic groups with respect to ancestry/race [37],
socioeconomic factors [5], and dietary and lifestyle risk
factors for cardiovascular disease [38]. However, our study
was not designed to explain why LVEF response and LVEF
decline seems to differ in different ethnic subgroups and
socioeconomic status was not one of the predictors of LVEF
decline. Similar to other studies [17–20], we found that AA
and Caucasians had similar response to BBs after 1 year and
similar post-response LVEF decline. However, other stud-
ies such as the beta-blocker evaluation of survival trial
(BEST) showed that AA patients had a worse HF prognosis
than Caucasians because of genetic differences [20]. A
genetic substudy of the BEST data, which evaluated the
effects of BBs among differing B-gene polymorphisms
Table 3 Differences in change in LVEF between different races (patients with post-response LVEF decline and patients with sustained LVEF
response)
All NICM (N = 238) Caucasians (n = 52) Hispanics (n = 78) AA (n = 108) p Value
Post-response LVEF decline [n (%)] 32 6 (19) 14 (44) 12 (38) 0.288
Baseline LVEF before BB [median (IQR)] 30 (24–35) 34 (24–42) 32 (22–36) 27 (19–31) 0.024
LVEF after 1 year of BB [median (IQR)] 41 (29–52) 47 (35–50) 40 (30–48) 45 (36–52) \0.01
Post-response nadir LVEF [median (IQR)] 25 (20–29) 27 (20–31) 22 (20–25) 26 (24–32) \0.01
Sustained LVEF response [n (%)] 206 47 (23) 60 (29) 99 (48) 0.147
Baseline LVEF before BB [median (IQR)] 29 (23–36) 27 (22–30) 30 (20–38) 30 (25–35) 0.036
LVEF after 1 year of BB [median (IQR)] 47 (35–54) 49 (38–55) 38 (22–41) 44 (34–48) \0.01
Post-response nadir LVEF [median (IQR)] 40 (25–44) 42 (31–46) 32 (25–37) 36 (28–40) 0.005
p value for comparison of different races
AA African Americans, BB beta blocker, IQR interquartile range, LVEF left ventricular ejection fraction, NICM non-ischemic cardiomyopathy
Fig. 2 Change in LVEF after BB in patients with NICM. Compared
with other races, Hisp had a lower LVEF increase after 1 year of BB
(p \ 0.01) and lower nadir LVEF in both the post-response LVEF
decline group (22 %, p \ 0.01) and sustained LVEF response group
(32 %, p \ 0.01). AA African Americans, BB beta blocker, Cauc
Caucasians, Hisp Hispanics, LVEF left ventricular ejection fraction,
NICM non-ischemic cardiomyopathy
Table 4 Important predictors of post-response LVEF decline (mul-
tivariable logistic regression). Final models adjusted for important
clinical characteristics such as age, gender, NYHA class
Predictors Post-response LVEF decline (n = 32)
Unadjusted Adjusted
OR p value OR p value
Baseline LVEF (overall) 1.047 0.038 1.075 0.029
Race (white is reference)
Hispanic race 3.128 0.003 6.094 \0.001
AA 0.926 0.842 0.595 0.224
NYHA class 1.431 0.240 2.287 0.035
BB dose (low dose of BB is reference)
Medium-dose BB 1.553 0.259 1.220 0.687
High-dose BB 0.420 0.069 0.312 0.063
ACEI/ARB 0.765 0.738 0.532 0.472
Gender 0.652 0.265 0.951 0.910
Age 0.960 0.005 0.933 \0.001
AA African Americans, ACEI angiotensin-converting enzyme inhib-
itors, ARB Angiotensin II receptor blockers, BB beta blocker, LVEF
left ventricular ejection fraction, NYHA New York Heart Association,
OR odds ratio
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showed that patients with certain beta receptor genotypes
were associated with the better clinical response to BBs
compared with others [15, 29–32]. Another study showed
that carvedilol significantly increased LVEF in CHF
patients with the Glu(27)beta(2)-adrenergic receptor allele
[39]. Therefore differences in LVEF response to BBs [40,
41] could be attributed to genetic differences. Hispanic
patients with NICM may have genetic polymorphisms that
could explain why this racial group may be more suscep-
tible to post-response LVEF decline compared with other
races. In this regard, the interactions between Hispanic race,
care-seeking behavior, and access to high-quality HF care
remain important areas for future investigation, and future
research aimed at analyzing polymorphisms among His-
panics and AA may yield interesting results.
Whether there is any variable that can predict mainte-
nance of LVEF after initial response to BB therapy in
patients with HF remains to be discovered. Our study
showed that age and NYHA class were important predic-
tors of LVEF response compared with other predictors such
as BB dose. These results are consistent with prior studies
that have shown that age and NYHA class have a strong
association with LVEF response to BBs [14, 22]. Regard-
ing dosing of BBs, in the multicenter oral carvedilol
heart failure assessment (MOCHA) trial, carvedilol
(12.5–50 mg/day) generated dose-related LVEF improve-
ment (5–8 %) in HF patients, of whom 77 % were Cau-
casians [7]. The carvedilol dose in our patients was about
the same dose as that used in the MOCHA trial, but the
magnitude of the LVEF improvement for Caucasians in our
study was higher. Although this finding is consistent with
other studies [10, 42, 43], to the best of our knowledge
there are no prior studies regarding BB dosing and LVEF
response in Hispanics. In our study, we also confirmed the
finding that the effect of BBs on LVEF response was
similar irrespective of type of BB used (metoprolol or
carvedilol) [10, 42, 43]. Therefore, Hispanics with NICM
may have worse post-response LVEF decline irrespective
of BB dose and type of BB used compared with other races.
Given that prior data have shown differences in LVEF
response to BBs [15, 29–32, 40, 41] due to genetic dif-
ferences (B-gene polymorphisms), genetic background
might explain variation in post-response LVEF decline
[15].
Finally, baseline LVEF was an important predictor of
post-response LVEF decline. Our data is consistent with
prior studies that have shown that baseline LVEF has a
significant association with response to BB therapy [9, 10].
The increase in LVEF is greater in patients with lower
baseline LVEF after treatment with BB therapy [9]. The
down-regulation of beta-1-receptor density may be greater
with higher chronic catecholamine exposure, which may be
the case with more severe cardiomyopathy [10]. BB ther-
apy may then up-regulate beta-1-receptor density to a
greater extent in these more severe disease states.
Due to the retrospective nature of the study, expected
limitations were encountered. The number of patients
enrolled in this study precluded restriction of analyses to
only those with low ejection fraction or only those with
symptoms of HF. Those variables that were determined by
self-report or review of the medical records are beyond the
control of the investigators and, thus, subject to error.
There was also a lack of availability of data on medical
therapy and a lack of information regarding socioeconomic
status, including education and income, that may have had
an effect on HF outcomes. In addition, this is a single-
center study and the findings may not confer external
validity. In our Hispanic population, we did not identify
special subgroups such as Mexican-origin Hispanics versus
those of Caribbean-origin, subgroups which have been
shown to have differences in LV remodeling parameters
[34, 35]. Finally, the methods used in this study serve only
to describe statistical associations between variables, which
are not necessarily proof of causation.
5 Conclusion
A significant proportion (13.44 %) of NICM patients who
experienced an improvement in LVEF with BB therapy in
the first year had a subsequent decline. Race, NYHA class,
baseline LVEF, and age are important predictors of post-
response LVEF decline. An underlying genetic difference
may explain differences in LVEF response to BB therapy
observed in this study. Future studies should evaluate
genetic polymorphisms affecting beta-adrenoceptor func-
tion in patients with NICM.
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